> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Akorn Generic Allergy Nasal Spray Approved
- URL: https://www.fdaweb.com/akorn-generic-allergy-nasal-spray-approved/
- Published: 2019-08-26T12:00:00.000Z
- Updated: 2026-09-15T01:46:09.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5144857

FDA has approved an Akorn ANDA for azelastine hydrochloride nasal spray, 0.15%, indicated for relieving symptoms of seasonal allergic rhinitis and perennial allergic rhinitis in patients six years of age and older. U.S. annual sales of azelastine hydrochloride nasal spray are about $18 million. The product will be manufactured at Akorn’s Amityville, NY manufacturing facility.